Cancer chemotherapy-induced cardiotoxicity is concerning. Certain anthracyclines and targeted therapies are known to have potential for cardiotoxicity, but existing trial evidence is inadequate to understand real-world patterns of cardiotoxicity with newer targeted therapies and their common combinations with older agents. This study evaluated chemotherapy-related cardiotoxicity reports for targeted therapies and their combinations in breast cancer patients.
Methods
The US Food and Drug Administration Adverse Event Reporting System (FAERS) database from January 2004 through September 2012 was used to summarize characteristics of reported cardiotoxicity events and their health outcomes. Disproportionality analyses with reporting odds ratios (ROR) and 95% confidence intervals (95% CI) were conducted to detect event signals using a case/non-case method for each targeted therapy and combination.
Results
A total of 59,739 cases of cardiotoxicity reports were identified; 937 cases identified targeted therapy as the suspect drug. Trastuzumab had the highest number of reports followed by bevacizumab and lapatinib. Proportions of reports of death and disability outcomes for each targeted therapy were approximately 20–25% of the total reports of serious events. Trastuzumab had the highest ROR as a single agent (ROR = 5.74; 95% CI = 5.29–6.23) or combination use of cyclophosphamide (ROR = 16.83; 95% CI = 13.32–21.26) or doxorubicin (ROR = 17.84; 95% CI = 13.77–23.11). Relatively low cardiotoxicity reporting rates were found with lapatinib, regardless of use with combination therapy.
Conclusions
Analysis of FAERS data identified signals for adverse cardiotoxicity events with targeted therapies and their combinations. Practitioners should consider factors that may increase the likelihood of cardiotoxicity when assessing treatment. Findings support continued surveillance, risk factor identification, and comparative studies.
SvobodaMPoprachADobesS. Cardiac toxicity of targeted therapies used in the treatment for solid tumours: a review. Cardiovasc Toxicol2012; 12: 191–207.
3.
BowlesEJWellmanRFeigelsonHS. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: A retrospective cohort study. J Natl Cancer Inst2012; 104: 1293–1305.
4.
ChenJLongJBHurriaA. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol2012; 60: 2504–2512.
5.
ChenTXuTLiY. Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis. Cancer Treat Rev2011; 37: 312–320.
6.
ZambelliADella PortaMGEleuteriE. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues. Breast2011; 20: 176–183.
7.
PerezEAKoehlerMByrneJ. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc2008; 83: 679–686.
8.
BaselgaJGelmonKAVermaS. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol2010; 28: 1138–1144.
9.
SwainSMEwerMSCortesJ. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. Oncologist2013; 18: 257–264.
10.
HallPSHarshmanLCSrinivasS. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. JACC Heart Fail2013; 1: 72–78.
11.
National Comprehensive Cancer Network. NCCN Clinican Practice Guideline in Oncology (NCCN Guideline) Version 3.2104. 2014.
12.
CardosoFHarbeckNFallowfieldL. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol2012; 23: vii11–9.
13.
AebiSDavidsonTGruberG. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol2011; 22: vi12–24.
14.
RaysonDRichelDChiaS. Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies. Ann Oncol2008; 19: 1530–1539.
15.
SmithIProcterMGelberRD. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet2007; 369: 29–36.
16.
GeyerCEForsterJLindquistD. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med2006; 355: 2733–2743.
17.
BlackwellKLBursteinHJStornioloAM. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol2010; 28: 1124–1130.
18.
GradisharWJAndersonBOBlairSL. Breast cancer version 3.2014. J Natl Compr Canc Netw2014; 12: 542–590.
19.
BaselgaJCortesJKimSB. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med2012; 366: 109–119.
MojaLTagliabueLBalduzziS. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev2012; 4: CD006243.
22.
YancyCWJessupMBozkurtB. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation2013; 128: e240–e327.
23.
SmithKLDangCSeidmanAD. Cardiac dysfunction associated with trastuzumab. Expert Opin Drug Safe2006; 5: 619–29.
24.
SingerCFKostlerWJHudelistG. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies. Biochim Biophys Acta2008; 1786: 105–113.
25.
CardinaleDColomboATorrisiR. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol2010; 28: 3910–3916.
26.
SlamonDJLeyland-JonesBShakS. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med2001; 344: 783–792.
27.
AhmadSR. Adverse drug event monitoring at the Food and Drug Administration. J Gen Intern Med2003; 18: 57–60.
SakaedaTTamonAKadoyamaK. Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci2013; 10: 796–803.
30.
AlbiniAPennesiGDonatelliF. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst2010; 102: 14–25.
31.
AlmenoffJTonningJMGouldAL. Perspectives on the use of data mining in pharmaco-vigilance. Drug Safe2005; 28: 981–1007.
32.
van PuijenbroekEPBateALeufkensHG. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Safe2002; 11: 3–10.
33.
SchultzPNBeckMLStavaC. Health profiles in 5836 long-term cancer survivors. Int J Cancer2003; 104: 488–495.
34.
SheppardRJBergerJSebagIA. Cardiotoxicity of cancer therapeutics: current issues in screening, prevention, and therapy. Front Pharmacol2013; 4: 19.
35.
SwainSMWhaleyFSEwerMS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer2003; 97: 2869–2879.
36.
FloydJDNguyenDTLobinsRL. Cardiotoxicity of cancer therapy. J Clin Oncol2005; 23: 7685–7696.
37.
SeidmanAHudisCPierriMK. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol2002; 20: 1215–1221.
YehETTongATLenihanDJ. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation2004; 109: 3122–3131.
40.
BovelliDPlataniotisGRoilaF. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol2010; 21: v277–v282.
41.
PituskinEHaykowskyMMackeyJR. Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101–Breast): A randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI. BMC Cancer2011; 11: 318.
42.
JoensuuHKellokumpu-LehtinenPLBonoP. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med2006; 354: 809–820.
43.
SlamonDEiermannWRobertN. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med2011; 365: 1273–1283.
44.
BurrisH3rdYardleyDJonesS. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. J Clin Oncol2004; 22: 1621–1629.
45.
PegramMDPienkowskiTNorthfeltDW. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst2004; 96: 759–769.
FuMZhouJSunA. Efficacy of ACE inhibitors in chronic heart failure with preserved ejection fraction – A meta analysis of 7 prospective clinical studies. Int J Cardiol2012; 155: 33–38.
48.
MeuneCWahbiKDubocD. Meta-analysis of Renin-Angiotensin-aldosterone blockade for heart failure in presence of preserved left ventricular function. J Cardiovasc Pharmacol Ther2011; 16: 368–375.
49.
KalamKMarwickTH. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: A systematic review and meta-analysis. Eur J Cancer2013; 49(13): 2900–2909. .
50.
BirdBRSwainSM. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res2008; 14: 14–24.
51.
RothmanKJLanesSSacksST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Safe2004; 13: 519–523.
52.
van der HeijdenPGvan PuijenbroekEPvan BuurenS. On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of under-reporting on odds ratios. Stat Med2002; 21: 2027–2044.
